Investor presentation Full year 2019 56 ecedented weight loss in a phase Key results and next steps • Participants in the highest dose arms continued to lose weight over the duration of the trial as the response curve did not plateau in the highest dose arm • Nearly two out of three patients experienced a weight loss of 10% or more with the highest dose of semaglutide • 80% of patients completed the trial • Once-daily semaglutide had a well-tolerated safety profile, with the most common adverse events being gastrointestinal • Phase 3a programme STEP and cardiovascular outcomes study SELECT were initiated in 2018
Download PDF file